Advancing MRD as a Surrogate Endpoint in Precision Oncology
- Evaluating the clinical and analytical validation required for MRD to serve as a reliable surrogate endpoint across tumor types
- Aligning trial design, assay sensitivity, and timepoint selection to generate robust, regulator-ready evidence
- Exploring how MRD-driven endpoints could accelerate development timelines and inform earlier treatment decisions